- Guide to PHARMACOLOGY
Compound class: Antibody
Comment: Vunakizumab (SHR-1314) is an investigational, humanized monoclonal antibody targeting IL17A, with potential use in autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A patent literature search identifies peptide sequences in WO2015070697, which are identical matches to the heavy and light chain variable regions of vunakizumab (SEQ ID NO 5 and 9 respectively) . These sequences belong to antibody coded Hu049.
|No information available.|
|Summary of Clinical Use|
|Vunakizumab (SHR-1314) has advanced to clinical evaluation in patients with psoriasis.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04121143||A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults||Phase 2 Interventional||Jiangsu HengRui Medicine Co., Ltd.||Jiangsu Hengrui Medicine have suspended this trial; the reason is unclear.|